It is still debated whether patients treated with statins are more or less prone to occurrence of neoplasia and whether statin treatment can affect the therapy outcome of these patients [15], [16]; thus, we analyzed whether fluvastatin can influence ADCC elicited through the engagement of human FcγRIIIA (namely CD16) on NK cells in two different experimental settings: a) lysis of CD20+ C1R lymphoma target cells with the anti-CD20 rituximab; b) killing of HER2+ SKBR3 breast adenocarcinoma cell line using the anti-HER2 antibody trastuzumab. Here, FCGR3A is linked to breast adenocarcinoma.